JPWO2019246486A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019246486A5 JPWO2019246486A5 JP2020570813A JP2020570813A JPWO2019246486A5 JP WO2019246486 A5 JPWO2019246486 A5 JP WO2019246486A5 JP 2020570813 A JP2020570813 A JP 2020570813A JP 2020570813 A JP2020570813 A JP 2020570813A JP WO2019246486 A5 JPWO2019246486 A5 JP WO2019246486A5
- Authority
- JP
- Japan
- Prior art keywords
- transposase
- seq
- tcbuster transposase
- amino acid
- mutant tcbuster
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000008579 Transposases Human genes 0.000 claims description 51
- 108010020764 Transposases Proteins 0.000 claims description 51
- 210000004027 cell Anatomy 0.000 claims description 37
- 230000004927 fusion Effects 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 15
- 108091033319 polynucleotide Proteins 0.000 claims description 11
- 102000040430 polynucleotide Human genes 0.000 claims description 11
- 239000002157 polynucleotide Substances 0.000 claims description 11
- 238000004520 electroporation Methods 0.000 claims description 9
- 108020004414 DNA Proteins 0.000 claims description 6
- 108020004999 messenger RNA Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical group 0.000 claims description 5
- 238000001890 transfection Methods 0.000 claims description 5
- 239000013598 vector Substances 0.000 claims description 4
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 3
- 239000001506 calcium phosphate Substances 0.000 claims description 3
- 235000011010 calcium phosphates Nutrition 0.000 claims description 3
- 229920006317 cationic polymer Polymers 0.000 claims description 3
- 239000000412 dendrimer Substances 0.000 claims description 3
- 229920000736 dendritic polymer Polymers 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 238000000520 microinjection Methods 0.000 claims description 3
- 230000003287 optical effect Effects 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 210000001938 protoplast Anatomy 0.000 claims description 3
- 238000000527 sonication Methods 0.000 claims description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 3
- 239000013612 plasmid Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 238000006467 substitution reaction Methods 0.000 claims 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 7
- 238000010362 genome editing Methods 0.000 claims 3
- 102220036871 rs587780095 Human genes 0.000 claims 3
- 230000009870 specific binding Effects 0.000 claims 3
- 102220475071 Bifunctional arginine demethylase and lysyl-hydroxylase JMJD6_D189A_mutation Human genes 0.000 claims 2
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims 2
- 102220230163 rs773532701 Human genes 0.000 claims 2
- 230000017105 transposition Effects 0.000 claims 2
- 230000004568 DNA-binding Effects 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 238000000530 impalefection Methods 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 description 6
- 108700019146 Transgenes Proteins 0.000 description 3
- 230000005684 electric field Effects 0.000 description 3
- 108091008875 B cell receptors Proteins 0.000 description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 210000004986 primary T-cell Anatomy 0.000 description 2
- 210000004990 primary immune cell Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 102100029812 Protein S100-A12 Human genes 0.000 description 1
- 101710110949 Protein S100-A12 Proteins 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000002514 epidermal stem cell Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 210000004966 intestinal stem cell Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004216 mammary stem cell Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024001350A JP7733865B2 (ja) | 2018-06-21 | 2024-01-09 | 強化されたｈＡＴファミリーのトランスポゾンが介在する遺伝子導入ならびに関連する組成物、システム、及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862688278P | 2018-06-21 | 2018-06-21 | |
| US62/688,278 | 2018-06-21 | ||
| PCT/US2019/038410 WO2019246486A2 (en) | 2018-06-21 | 2019-06-21 | ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024001350A Division JP7733865B2 (ja) | 2018-06-21 | 2024-01-09 | 強化されたｈＡＴファミリーのトランスポゾンが介在する遺伝子導入ならびに関連する組成物、システム、及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021527427A JP2021527427A (ja) | 2021-10-14 |
| JPWO2019246486A5 true JPWO2019246486A5 (https=) | 2023-08-02 |
| JP2021527427A5 JP2021527427A5 (https=) | 2023-08-02 |
Family
ID=67211911
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020570813A Pending JP2021527427A (ja) | 2018-06-21 | 2019-06-21 | 強化されたｈＡＴファミリーのトランスポゾンが介在する遺伝子導入ならびに関連する組成物、システム、及び方法 |
| JP2024001350A Active JP7733865B2 (ja) | 2018-06-21 | 2024-01-09 | 強化されたｈＡＴファミリーのトランスポゾンが介在する遺伝子導入ならびに関連する組成物、システム、及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024001350A Active JP7733865B2 (ja) | 2018-06-21 | 2024-01-09 | 強化されたｈＡＴファミリーのトランスポゾンが介在する遺伝子導入ならびに関連する組成物、システム、及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11760983B2 (https=) |
| EP (1) | EP3810764A2 (https=) |
| JP (2) | JP2021527427A (https=) |
| CN (1) | CN112543808A (https=) |
| AU (1) | AU2019288669B2 (https=) |
| CA (1) | CA3104288A1 (https=) |
| WO (1) | WO2019246486A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019288669B2 (en) * | 2018-06-21 | 2025-06-26 | R&D Systems, Inc. | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods |
| US20230272355A1 (en) * | 2020-06-05 | 2023-08-31 | B-Mogen Biotechnologies, Inc. | ENHANCED hAT FAMILY MEMBER SPIN TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS |
| CA3201499A1 (en) | 2020-11-13 | 2022-05-19 | Catamaran Bio, Inc. | Genetically modified natural killer cells and methods of use thereof |
| WO2022115611A1 (en) | 2020-11-25 | 2022-06-02 | Catamaran Bio, Inc. | Cellular therapeutics engineered with signal modulators and methods of use thereof |
| WO2023004366A1 (en) | 2021-07-21 | 2023-01-26 | Aspen Neuroscience, Inc. | Transposon-based modulation of gba1 and related compositions and uses thereof |
| WO2023172514A1 (en) | 2022-03-07 | 2023-09-14 | Catamaran Bio, Inc. | Engineered immune cell therapeutics targeted to her2 and methods of use thereof |
| JP2025516189A (ja) | 2022-04-28 | 2025-05-27 | イマティクス ユーエス，アイエヌシー． | 膜結合型ｉｌ－１５、ｃｄ８ポリペプチド、細胞、組成物、およびそれらの使用方法 |
| JP2025515603A (ja) | 2022-04-28 | 2025-05-20 | イマティクス ユーエス，アイエヌシー． | Ｉｌ－１２ポリペプチド、ｉｌ－１５ポリペプチド、ｉｌ－１８ポリペプチド、ｃｄ８ポリペプチド、それらの組成物、およびそれらの使用方法 |
| JP2025515604A (ja) | 2022-04-28 | 2025-05-20 | イマティクス ユーエス，アイエヌシー． | ドミナントネガティブＴＧＦβ受容体ポリペプチド、ＣＤ８ポリペプチド、細胞、組成物、およびその使用方法 |
| WO2025054409A1 (en) * | 2023-09-07 | 2025-03-13 | Bio-Techne Corporation | Mutant tcbuster transposase with improved solubility |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1339863A2 (en) | 2000-12-05 | 2003-09-03 | Wisconsin Alumni Research Foundation | Double transposition methods for manipulating nucleic acids |
| US7064246B2 (en) | 2001-05-01 | 2006-06-20 | Macrae Amy F | Use of transposable elements for altering gene expression |
| US7262056B2 (en) | 2001-11-08 | 2007-08-28 | Mirus Bio Corporation | Enhancing intermolecular integration of nucleic acids using integrator complexes |
| EP1458875A2 (de) | 2001-12-20 | 2004-09-22 | Sungene GmbH & Co. KGaA | Verfahren zur transformation von pflanzlichen plastiden |
| ATE498016T1 (de) | 2003-02-10 | 2011-02-15 | Max Delbrueck Centrum | Transposon-system zur gezielten integration |
| DK1594973T3 (da) | 2003-02-10 | 2012-02-13 | Max Delbrueck Centrum | Transposonbaseret målretningssystem |
| GB2403475B (en) | 2003-07-01 | 2008-02-06 | Oxitec Ltd | Stable integrands |
| WO2005062881A2 (en) | 2003-12-24 | 2005-07-14 | Transgenrx, Inc. | Gene therapy using transposon-based vectors |
| US20060252140A1 (en) | 2005-04-29 | 2006-11-09 | Yant Stephen R | Development of a transposon system for site-specific DNA integration in mammalian cells |
| EP1921140B1 (en) | 2005-07-05 | 2011-12-14 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Mutant transposon vector and use thereof |
| EP2160461B1 (en) | 2007-07-04 | 2012-08-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Hyperactive variants of the transposase protein of the transposon system sleeping beauty |
| US8524979B2 (en) | 2008-04-14 | 2013-09-03 | National Taiwan University | Termination of transgene expression via transposon-mediated break |
| US20110239315A1 (en) | 2009-01-12 | 2011-09-29 | Ulla Bonas | Modular dna-binding domains and methods of use |
| WO2010099296A1 (en) | 2009-02-26 | 2010-09-02 | Transposagen Biopharmaceuticals, Inc. | Hyperactive piggybac transposases |
| BRPI1010759B1 (pt) | 2009-06-11 | 2019-07-16 | Inter-University Research Institute Corporation Research Organization Of Information And Systems | Método para produzir uma proteína de interesse ou para obter uma suspensão de células de mamíferos capaz de produzir uma proteína de interesse, bem como vetor de expressão de proteína |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US20130017978A1 (en) | 2011-07-11 | 2013-01-17 | Finnzymes Oy | Methods and transposon nucleic acids for generating a dna library |
| WO2013040557A2 (en) | 2011-09-16 | 2013-03-21 | The Trustees Of The University Of Pennsylvania | Rna engineered t cells for the treatment of cancer |
| DK3141259T3 (da) | 2012-03-15 | 2019-09-30 | Cellectis | Repeat-variable direster til targeting af nukleotider |
| ES2528892T3 (es) | 2012-07-30 | 2015-02-13 | Nbe-Therapeutics Llc | Identificación mediada por trasposición de proteínas de unión o funcionales específicas |
| DK3536797T5 (da) | 2013-02-01 | 2024-09-02 | Selexis Sa | Forhøjet transgenudtrykkelse og -forarbejdning |
| EP3783098A1 (en) | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| CA2943296C (en) | 2014-03-21 | 2022-10-18 | The Sydney Children's Hospitals Network (Randwick And Westmead) (Incorporating The Royal Alexandra Hospital For Children) | Stable gene transfer to proliferating cells |
| CN103981204B (zh) | 2014-03-24 | 2016-05-04 | 上海海洋大学 | 一种有活性的金鱼Tgf2转座子重组转座酶蛋白的表达方法 |
| US9534234B2 (en) | 2014-04-09 | 2017-01-03 | Dna2.0, Inc. | Enhanced nucleic acid constructs for eukaryotic gene expression |
| EP3157328B1 (en) | 2014-06-17 | 2021-08-04 | Poseida Therapeutics, Inc. | A method for directing proteins to specific loci in the genome and uses thereof |
| AU2015323973A1 (en) | 2014-09-29 | 2017-04-20 | The Jackson Laboratory | High efficiency, high throughput generation of genetically modified mammals by electroporation |
| EP3018200A1 (en) | 2014-11-07 | 2016-05-11 | Fondazione Matilde Tettamanti e Menotti de Machi Onlus | Improved method for the generation of genetically modified cells |
| KR20250171479A (ko) | 2015-03-31 | 2025-12-08 | 소흠, 인코포레이티드 | 세포 또는 유기체의 게놈으로의 ＤＮＡ 서열의 표적화 혼입을 위한 Ｃａｓ 9 레트로바이러스 인테그라제 시스템 및 Ｃａｓ 9 재조합효소 시스템 |
| ES2926467T3 (es) | 2015-04-13 | 2022-10-26 | Maxcyte Inc | Métodos y composiciones para la modificación del ADN genómico |
| US20180087050A1 (en) | 2015-05-27 | 2018-03-29 | Jianbiao Zheng | Methods of inserting molecular barcodes |
| EP3929286A1 (en) | 2015-06-17 | 2021-12-29 | Poseida Therapeutics, Inc. | Compositions and methods for directing proteins to specific loci in the genome |
| EP3350335B1 (en) | 2015-09-16 | 2019-11-27 | T-CURX GmbH | Improved transposon system for gene delivery |
| EP4706680A3 (en) | 2015-09-22 | 2026-03-25 | Julius-Maximilians-Universität Würzburg | A method for high level and stable gene transfer in lymphocytes |
| CN105154473B (zh) | 2015-09-30 | 2019-03-01 | 上海细胞治疗研究院 | 一种高效安全的转座子整合系统及其用途 |
| EP4289944A3 (en) | 2015-10-08 | 2024-03-13 | National University Corporation Tokai National Higher Education and Research System | Method for preparing genetically-modified t cells which express chimeric antigen receptor |
| JP6956416B2 (ja) | 2015-12-14 | 2021-11-02 | ゲノムフロンティア セラピューティクス，インコーポレイテッド | トランスポゾン系、それを含むキット及びそれらの使用 |
| US20190169602A1 (en) | 2016-01-12 | 2019-06-06 | Seqwell, Inc. | Compositions and methods for sequencing nucleic acids |
| KR20190003938A (ko) | 2016-02-25 | 2019-01-10 | 셀 메디카 스위처란트 아게 | 면역치료를 위한 변형된 세포 |
| CA3015642A1 (en) | 2016-02-26 | 2017-08-31 | Poseida Therapeutics, Inc. | Transposon system and methods of use |
| EP3219800A1 (en) | 2016-03-15 | 2017-09-20 | Max-Delbrück-Centrum Für Molekulare Medizin | A transposon-based transfection system for primary cells |
| CN118147079A (zh) | 2016-03-31 | 2024-06-07 | 来恩生物医药私人有限公司 | 表达外源病毒特异性t细胞受体(tcr)的非活化t细胞 |
| CA3022267A1 (en) | 2016-05-04 | 2017-11-09 | Fred Hutchinson Cancer Research Center | Cell-based neoantigen vaccines and uses thereof |
| CN114891751A (zh) | 2016-06-20 | 2022-08-12 | 上海细胞治疗研究院 | 一种高效稳定表达激活型抗体的car-t细胞及其用途 |
| CN107523545A (zh) | 2016-06-20 | 2017-12-29 | 上海细胞治疗研究院 | 一种高效稳定表达抗体的杀伤性细胞及其用途 |
| CN107523548A (zh) | 2016-06-20 | 2017-12-29 | 上海细胞治疗研究院 | 一种高效稳定表达抗体的t细胞及其用途 |
| CN107523547A (zh) | 2016-06-20 | 2017-12-29 | 上海细胞治疗研究院 | 一种高效稳定表达抑制性抗体的car‑t细胞及其用途 |
| KR20190031306A (ko) | 2016-07-21 | 2019-03-25 | 맥스시티 인코포레이티드 | 게놈 dna를 변경하기 위한 방법 및 조성물 |
| US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
| EP3508574B1 (en) | 2016-08-30 | 2024-10-09 | Kyushu University, National University Corporation | Method for inserting desired dna fragment into site located adjacent to binding domain of dna-binding protein |
| WO2018057779A1 (en) | 2016-09-23 | 2018-03-29 | Jianbiao Zheng | Compositions of synthetic transposons and methods of use thereof |
| SG11201901959YA (en) | 2016-09-30 | 2019-04-29 | Poseida Therapeutics Inc | Modified stem cell memory t cells, methods of making and methods of using same |
| MA46959A (fr) | 2016-12-02 | 2019-10-09 | Juno Therapeutics Inc | Cellules b modifiées et compositions et méthodes associées |
| AU2017378482B2 (en) * | 2016-12-16 | 2024-06-13 | R&D Systems, Inc. | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods |
| KR20190102259A (ko) | 2017-01-10 | 2019-09-03 | 인트렉손 코포레이션 | 신규의 유전자 스위치 발현 시스템을 통한 폴리펩티드의 발현 조절 |
| WO2018140644A1 (en) | 2017-01-25 | 2018-08-02 | Musc Foundation For Research Development | Modified t cells and uses thereof |
| AU2019288669B2 (en) * | 2018-06-21 | 2025-06-26 | R&D Systems, Inc. | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods |
-
2019
- 2019-06-21 AU AU2019288669A patent/AU2019288669B2/en active Active
- 2019-06-21 WO PCT/US2019/038410 patent/WO2019246486A2/en not_active Ceased
- 2019-06-21 CA CA3104288A patent/CA3104288A1/en active Pending
- 2019-06-21 CN CN201980051568.7A patent/CN112543808A/zh active Pending
- 2019-06-21 US US17/254,162 patent/US11760983B2/en active Active
- 2019-06-21 JP JP2020570813A patent/JP2021527427A/ja active Pending
- 2019-06-21 EP EP19737385.5A patent/EP3810764A2/en active Pending
-
2024
- 2024-01-09 JP JP2024001350A patent/JP7733865B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102780441B1 (ko) | Cas-형질전환 마우스 배아 줄기 세포 및 마우스 및 이것의 용도 | |
| JP2025028917A (ja) | 核酸構築物及び使用方法 | |
| CN110730821B (zh) | 增强的hAT家族转座子介导的基因转移及相关组合物、系统和方法 | |
| JP2020501612A5 (https=) | ||
| CN112543808A (zh) | 增强的hAT家族转座子介导的基因转移及相关组合物、系统和方法 | |
| WO2010105277A1 (en) | Compositions and methods for the delivery of biologically active rnas | |
| JPWO2019246486A5 (https=) | ||
| AU2012358181A1 (en) | Compositions and methods for the delivery of biologically active RNAs | |
| EP4141119A2 (en) | Hairpin loop ended self-complementary double-stranded covalently closed linear dna vector, manufacturing system and process, and uses of said resulting dna vector | |
| WO2024240138A1 (zh) | 基于perv逆转录酶的先导编辑系统 | |
| CN110891419A (zh) | 评价crispr/cas-诱导的与外源供体核酸的体内重组 | |
| US12419915B2 (en) | Microglial progenitors for regeneration of functional microglia in the central nervous system and therapeutics uses thereof | |
| WO2024041653A1 (zh) | 一种CRISPR-Cas13系统及其应用 | |
| CN114164231A (zh) | 对细胞中的靶位点进行基因编辑的方法 | |
| KR20240117571A (ko) | 돌연변이 마이오실린 질환 모델 및 이의 용도 | |
| WO2024040202A1 (en) | Fusion proteins and uses thereof for precision editing | |
| US20260101880A1 (en) | Genetic complementation compositions and methods | |
| JP2025514304A (ja) | 遺伝子治療法のための組織特異的遺伝子外セーフハーバーの同定 | |
| WO2025054409A1 (en) | Mutant tcbuster transposase with improved solubility | |
| WO2021247989A1 (en) | Enhanced hat family member spin transposon-mediated gene transfer and associated compositions, systems, and methods | |
| JP2025521154A (ja) | Ｃ９ｏｒｆ７２反復伸長疾患のためのｃｒｉｓｐｒ干渉療法 | |
| AU2024302819A1 (en) | Zinc finger protein, zinc finger nuclease, vector, and genome editing method using said substances | |
| WO2023085433A1 (ja) | ヒト細胞内でヒト人工染色体ベクターを作製する方法 | |
| WO2024131786A1 (zh) | 一种在基因组插入大片段dna的系统 |